What is it about?

Cervical cancer is the third most common malignant tumor and has become one of the major causes of cancer mortality. According to studies conducted recently; carbonic anhydrase IX (CAIX) is a particularly attractive target for cancer therapy, in part because it is limited as expressed in normal tissues on the other hand in a variety of solid neoplasms are overexpressed. Despite new methods and drugs to treat cervical cancer, there is a wide range of chemicals and natural products that have not yet been studied and tested as anticancer agents. - The aromatic sulfonamide derivative (S-1) is considered a new compound with great anti-cancer potential. - For the first time, the apoptotic, cytotoxic, and genotoxic properties of S-1 were studied in cervical cancer cell lines at various concentrations.

Featured Image

Why is it important?

Evaluation of the anticancer potential of a novel sulfonamide inhibitor of carboxylic anhydrase IX on cervical cancer cells was performed. The current original study was performed using a standard assay. Apoptosis and cell cycle induction were measured by flow cytometric analysis, and intracellular free radical induction was determined by reactive oxygen species (ROS) analyses.


The research looking for, discovering new drugs that more effectors to cancer are not stopping till now. Therefore, Researchers are constantly working towards developing renovated medicines that selectively kill tumor cells and protect healthy tissue with less many side effects. In this study, we report the specific inhibitory activity of a newly synthesized sulfonamide compound against carbonic anhydrase isoform IX. The target cell was a cervical cancer cell line (HeLa) synthesizing carbonic anhydrase isoform IX and the chemical used as anticancer agent was a newly synthesized sulfonamide compound as a specific inhibitor of this enzyme.

Van Yüzüncü Yıl University

Read the Original

This page is a summary of: Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells, Journal of Enzyme Inhibition and Medicinal Chemistry, January 2019, Taylor & Francis, DOI: 10.1080/14756366.2019.1579805.
You can read the full text:




The following have contributed to this page